Kailera Therapeutics (KLRA) CTO Nicholson received 220,000 Stock Option (right to buy)
Insider transactions reported
Nur Nicholson (Chief Technology Officer at Kailera Therapeutics Inc., KLRA) reported that they received 220,000 Stock Option (right to buy) on Sep 7, 2026.
- Reporting person
- Nicholson Nur
- Role
- Chief Technology Officer
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 7, 2026 | Grant or award (A) | Stock Option (right to buy)On 220,000 Common Stock1 | +220,000 | - | - | 220,000 direct |
Holdings before and after
- Stock Option (right to buy): 0 to 220,000 direct
Footnotes from the filing
- 1. The options vest and become exercisable as to 25% of the underlying shares on August 31, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Nicholson report in this KLRA Form 4?
Nur Nicholson (Chief Technology Officer at Kailera Therapeutics Inc., KLRA) reported that they received 220,000 Stock Option (right to buy) on Sep 7, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for KLRA
Across the 10 sessions after earlier KLRA headlines, the stock closed higher 3 times and lower 6 times, with a median move of 2.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | KLRA | SPY |
|---|---|---|---|
| Aug 13, 2026 | Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates | -3.3% | +0.7% |
| Aug 11, 2026 | Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer | -0.6% | -0.3% |
| Jul 7, 2026 | Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 | -4.5% | -0.5% |
| Jun 8, 2026 | Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026 | +1.7% | +0.2% |
| May 29, 2026 | Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference | +0.0% | +0.2% |
| May 27, 2026 | Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates | +1.6% | -0.0% |
Earlier insider filings at KLRA
- Jul 8, 2026SEC Form 4 filed by Officer Tregoning Kathleen
- Jun 11, 2026CEO & President Renaud Ronald C Jr exercised 38,094 shares at a strike of $5.25 (SEC Form 4)
- Apr 22, 2026SEC Form 4 filed by Rtw Investments, Lp
- Apr 22, 2026SEC Form 4 filed by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Apr 20, 2026SEC Form 4 filed by Bain Capital Investors Llc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2026
Follow KLRA and get a push notification the moment its next story breaks.